ES2992641T3 - Methylthioninium compounds for use in the treatment of hypoxemia - Google Patents

Methylthioninium compounds for use in the treatment of hypoxemia Download PDF

Info

Publication number
ES2992641T3
ES2992641T3 ES21724580T ES21724580T ES2992641T3 ES 2992641 T3 ES2992641 T3 ES 2992641T3 ES 21724580 T ES21724580 T ES 21724580T ES 21724580 T ES21724580 T ES 21724580T ES 2992641 T3 ES2992641 T3 ES 2992641T3
Authority
ES
Spain
Prior art keywords
compound
subject
use according
acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21724580T
Other languages
English (en)
Spanish (es)
Inventor
Mohammad Arastoo
Michael Philip Mazanetz
Claude Michel Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006659.3A external-priority patent/GB202006659D0/en
Priority claimed from GBGB2016957.9A external-priority patent/GB202016957D0/en
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Application granted granted Critical
Publication of ES2992641T3 publication Critical patent/ES2992641T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21724580T 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia Active ES2992641T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
GBGB2016957.9A GB202016957D0 (en) 2020-10-26 2020-10-26 Beneficial treatment
PCT/EP2021/061485 WO2021224146A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia

Publications (1)

Publication Number Publication Date
ES2992641T3 true ES2992641T3 (en) 2024-12-16

Family

ID=75887990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21724580T Active ES2992641T3 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia

Country Status (12)

Country Link
US (1) US20230158040A1 (https=)
EP (1) EP4146225B1 (https=)
JP (1) JP2023524146A (https=)
KR (1) KR20230012515A (https=)
CN (1) CN115916211A (https=)
AU (1) AU2021268465A1 (https=)
CA (1) CA3181388A1 (https=)
ES (1) ES2992641T3 (https=)
MX (1) MX2022013884A (https=)
PL (1) PL4146225T3 (https=)
TW (1) TWI907424B (https=)
WO (1) WO2021224146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) * 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
EP3982974A4 (en) * 2019-06-12 2023-06-21 Achal Narendrakumar Agrawal NOVEL IMPROVED PROCESS FOR THE SYNTHESIS OF DIAMINOPHENOTHIAZINE COMPOUNDS

Also Published As

Publication number Publication date
EP4146225B1 (en) 2024-10-09
TW202200149A (zh) 2022-01-01
BR112022022322A2 (pt) 2022-12-13
TWI907424B (zh) 2025-12-11
CN115916211A (zh) 2023-04-04
MX2022013884A (es) 2022-11-30
JP2023524146A (ja) 2023-06-08
WO2021224146A1 (en) 2021-11-11
US20230158040A1 (en) 2023-05-25
PL4146225T3 (pl) 2025-03-10
AU2021268465A1 (en) 2022-12-08
EP4146225C0 (en) 2024-10-09
EP4146225A1 (en) 2023-03-15
KR20230012515A (ko) 2023-01-26
CA3181388A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
ES2569123T3 (es) Infusión lenta de sulcardina y sus sales
ES2992641T3 (en) Methylthioninium compounds for use in the treatment of hypoxemia
RU2011147535A (ru) Терапевтическая комбинация, содержащая легочный сурфактант и стероид
US20230165875A1 (en) Methylthioninium compounds for use in the treatment of covid-19
BR112022022322B1 (pt) Uso de compostos de metiltionínio para preparação de medicamento oral para tratamento de hipoxemia
HK40088921B (en) Methylthioninium compounds for use in the treatment of hypoxemia
HK40088921A (en) Methylthioninium compounds for use in the treatment of hypoxemia
US20230165876A1 (en) Methylthioninium compounds for use in the treatment of covid-19
JP7603713B2 (ja) 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療
US20250222005A1 (en) Methylene blue containing compounds for the treatment of methaemoglobinaemia
ES2704649T3 (es) Gránulos estabilizados que contienen trinitrato de glicerilo para inducir la arteriogénesis
CN110891574A (zh) 用于预防和/或治疗肝细胞癌的美格列明